Rafael Holdings Inc. manufactures metabolic oncology drugs to treat cancer. The company's product pipeline consists of CPI-613, CPI-618, CPI-1826 and CPI-3220 which are in clinical stages. Rafael Holdings Inc. is based in Newark, United States.
| Revenue (Most Recent Fiscal Year) | $0.64M |
| Net Income (Most Recent Fiscal Year) | $-34.41M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 49.40 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.48 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -11946.03% |
| Net Margin (Trailing 12 Months) | -7148.16% |
| Return on Equity (Trailing 12 Months) | -58.04% |
| Return on Assets (Trailing 12 Months) | -51.35% |
| Current Ratio (Most Recent Fiscal Quarter) | 9.26 |
| Quick Ratio (Most Recent Fiscal Quarter) | 9.26 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $3.51 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.11 |
| Exchange | NYSE |
| Sector | Real Estate |
| Industry | Real Estate Services |
| Common Shares Outstanding | 24.91M |
| Free Float | 22.37M |
| Market Capitalization | $34.88M |
| Average Volume (Last 20 Days) | 0.14M |
| Beta (Past 60 Months) | 1.01 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 10.20% |
| Percentage Held By Institutions (Latest 13F Reports) | 11.30% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |